Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 2, 2008 - Issue
Submit an article Journal homepage
120
Views
0
CrossRef citations to date
0
Altmetric
Expert Opinion

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations

Akira Fujii1 Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan
,
Norio Yasui-Furukori1 Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, JapanCorrespondence[email protected]
,
Taku Nakagami1 Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan;3 Department of Neuropsychiatry, Ohdate City Hospital, Ohdate, Akita, Japan
,
Takenori Niioka4 Department of Pharmacy, Hirosaki University Hospital, Hirosaki, Japan
,
Manabu Saito1 Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan;2 Department of Psychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, Japan
,
Yasushi Sato1 Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan;2 Department of Psychiatry, Hirosaki-Aiseikai Hospital, Hirosaki, Japan
&
Sunao Kaneko1 Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan
 show all
Pages 139-144 | Published online: 11 Aug 2008

References

  • BialerM1992Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implicationsClin Pharmacokinet2211211559305
  • BowdenCLSinghV2005Valproate in bipolar disorder: 2000 onwardsActa Psychiatr Scand Suppl426132015833096
  • BuckDJacobyABakerGA1997Factors influencing compliance with antiepileptic drug regimesSeizure687939153719
  • CramerJVachonLDesforgesC1995Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trialEpilepsia36111177588455
  • DoughtyJBakerGAJacobyA2003Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsyEpilepsy Behav4710614698705
  • EadieMJ1991Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significanceClin Pharmacokinet2127411914340
  • FujisakiYTsukuneTFunyuM2006Development of sustained-release tablets containing sodium valproate: in vitro and in vivo correlationDrug Dev Ind Pharm322071716537201
  • GentonP2005Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproateActa Neurol Scand Suppl182263216359430
  • GuglerGvon UnruhGE1980Clinical pharmacokinetics of valproic acidClin Pharmacokinet567836767575
  • NasrallahHAKetterTAKalaliAH2006Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literatureJ Affect Disord95697816780960
  • PellockJMSmmithMCCloydJC2004Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapyEpilepsy Behav5301715145298
  • PeruccaE2002Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experienceCNS Drugs1669571412269862
  • PughCBGarnettWR1991Current issues in the treatment of epilepsyClin Pharm10335582049897
  • Yasui-FurukoriNSaitoMNakagamiT2007Different serum concentrations of steady-state valproic acid in two sustained-release formulationsPsychiatry Clin Neurosci613081217472600
  • ZaccaraGMessoriAMoroniF1988Clinical pharmacokinetics of valproic acid-1988Clin Pharmacokinet15367893149565

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.